THALES
16.4.2024 09:01:32 CEST | Business Wire | Press release
Thales, the cybersecurity leader that protects critical applications, APIs, and data, anywhere at scale, today announced the release of the 2024 Imperva Bad Bot Report, a global analysis of automated bot traffic across the internet. Nearly half (49.6%) of all internet traffic came from bots in 2023—a 2% increase over the previous year, and the highest level Imperva has reported since it began monitoring automated traffic in 2013.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416225637/en/
©Thales
For the fifth consecutive year, the proportion of web traffic associated with bad bots grew to 32% in 2023, up from 30.2% in 2022, while traffic from human users decreased to 50.4%. Automated traffic is costing organizations billions (USD) annually due to attacks on websites, APIs, and applications.
“Bots are one of the most pervasive and growing threats facing every industry,” says Nanhi Singh, General Manager, Application Security at Imperva, a Thales company. “From simple web scraping to malicious account takeover, spam, and denial of service, bots negatively impact an organization’s bottom line by degrading online services and requiring more investment in infrastructure and customer support. Organizations must proactively address the threat of bad bots as attackers sharpen their focus on API-related abuses that can lead to account compromise or data exfiltration.”
Key trends identified in the 2024 Imperva Bad Bot Report include:
- Global average of bad bot traffic reached 32%: Ireland (71%), Germany (67.5%), and Mexico (42.8%), saw the highest levels of bad bot traffic in 2023. The US also saw a slightly higher ratio of bad bot traffic at 35.4% compared to 2022 (32.1%).
- Growing use of generative AI connected to the rise in simple bots: Rapid adoption of generative AI and large language models (LLMs) resulted in the volume of simple bots increasing to 39.6% in 2023, up from 33.4% in 2022. The technology uses web scraping bots and automated crawlers to feed training models, while enabling nontechnical users to write automated scripts for their own use.
- Account takeover is a persistent business risk: Account takeover (ATO) attacks increased 10% in 2023, compared to the same period in the prior year. Notably, 44% of all ATO attacks targeted API endpoints, compared to 35% in 2022. Of all login attempts across the internet, 11% were associated with account takeover. The industries that saw the highest volume of ATO attacks in 2023 were Financial Services (36.8%), Travel (11.5%), and Business Services (8%).
- APIs are a popular vector for attack: Automated threats caused a significant 30% of API attacks in 2023. Among them, 17% were bad bots exploiting business logic vulnerabilities—a flaw within the API’s design and implementation that allows attackers to manipulate legitimate functionality and gain access to sensitive data or user accounts. Cybercriminals use automated bots to find and exploit APIs, which act as a direct pathway to sensitive data, making them a prime target for business logic abuse.
- Every industry has a bot problem: For a second consecutive year, Gaming (57.2%) saw the largest proportion of bad bot traffic. Meanwhile, Retail (24.4%), Travel (20.7%), and Financial Services (15.7%) experienced the highest volume of bot attacks. The proportion of advanced bad bots, those that closely mimic human behavior and evade defenses, was highest on Law & Government (75.8%), Entertainment (70.8%), and Financial Services (67.1%) websites.
- Bad bot traffic originating from residential ISPs grows to 25.8%: Early bad bot evasion techniques relied on masquerading as a user agent (browser) commonly used by legitimate human users. Bad bots masquerading as mobile user agents accounted for 44.8% of all bad bot traffic in the past year, up from 28.1% just five years ago. Sophisticated actors combine mobile user agents with the use of residential or mobile ISPs. Residential proxies allow bot operators to evade detection by making it appear as if the origin of the traffic is a legitimate, ISP-assigned residential IP address.
“Automated bots will soon surpass the proportion of internet traffic coming from humans, changing the way that organizations approach building and protecting their websites and applications,” continued Singh. “As more AI-enabled tools are introduced, bots will become omnipresent. Organizations must invest in bot management and API security tools to manage the threat from malicious, automated traffic.”
Additional Information:
- Download a copy of the 2024 Imperva Bad Bot Report for additional insights.
- See how Imperva Advanced Bot Protection, API Security, and Client-Side Protection can protect websites, mobile applications, and APIs from automated attacks and fraud without affecting the flow of business-critical traffic.
- Read the Imperva Blog for the latest product and solution news, and threat intelligence from Imperva Threat Research.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.
Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
* These figures exclude the ground transportation business, which is being divested
PLEASE VISIT
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416225637/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
